Form 483

Fresenius Kabi USA, LLC Form 483, 2019-08-12

FDA issued a Form 483 to Fresenius Kabi USA, LLC on 2019-08-12 with 4 public-safe observations.

483· Form 483 issuedHuman Drugs4 observations

Fresenius Kabi USA, LLC · Grand Island, United States · Issued August 12, 2019

Overview

  • 4 public-safe observations are available for this inspection.
  • 2 structured CFR citations are represented.
  • 3 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

12 Aug 2019
21 CFR 211.110(a)

Control procedures to monitor and validate performance

Cited by Rajiv R Srivastava, Marcellinus D Dordunoo, Johnna L Bleem

12 Aug 2019
21 CFR 211.110(a)

Control procedures to monitor and validate performance

Cited by Rajiv R Srivastava, Marcellinus D Dordunoo, Johnna L Bleem

12 Aug 2019
21 CFR 211.22(d)

Procedures not in writing, fully followed

Cited by Rajiv R Srivastava, Marcellinus D Dordunoo, Johnna L Bleem

12 Aug 2019
21 CFR 211.22(d)

Procedures not in writing, fully followed

Cited by Rajiv R Srivastava, Marcellinus D Dordunoo, Johnna L Bleem

Inspected site

FKFresenius Kabi USA, LLCGrand Island, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.110(a)Cited across public-safe Form 483 observations2x
21 CFR 211.22(d)Cited across public-safe Form 483 observations2x

Full 483 report

Get the verbatim text of all 4 observations

Every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere